

# Subject Index

## A

- ADCC 96, 117
- Adrenoceptor
  - Blockade 41
- Adriamycin 61
- Alloimmunity 46
- Allosensitization
  - Melanoma 99
- Antibody
  - Monoclonal 155, 196
  - Tumour 180
  - Xenogeneic 191
- Antigen
  - Fetal 78
  - Histocompatibility 133
  - Melanoma 191, 196
  - Murine leukemia 16
- Auto tumour stimulation 73

## B

- BCG 46, 92
- BCG-MER 4
- BCG-cell wall skeleton 167
- Brucella abortus 207

## C

- Chemiluminescence 86
- Chemoimmunotherapy 67, 202
- Cyclophosphamide 36
- Cytotoxicity
  - Lymphocyte 45, 54, 73, 82, 96, 99, 117, 137
  - Macrophage 61, 67

## E

- Endotoxin 41
- Epidemiology 110

## G

- Gastric cancer 167, 180

## H

- Helper cells 46
- Hepatoma
  - Line 10, 92, 151
- Hypersensitivity
  - Delayed type 59

## I

- Immunogenicity
  - Tumour 27
- Immunorestitution 145
- Immunoselection
  - Tumor variants 124
- Immunosuppression
  - Cyclophosphamide 36, 54
  - Tumour 36, 86
- Immunotherapy 4, 92, 151, 167
- Interferon 41

## K

- Klebsiella pneumoniae* 59

## L

- Leukemia
  - Acute 96
  - Murine 16
  - Myeloid 32
- Leukocytes
  - Migration assay 78
- Liposomes 61
- Lymphocyte
  - Cytotoxicity 54, 82, 99, 137
  - Helper 32
  - Suppressor 32

## M

- Macrophage 61, 67, 105
- Melanoma 78, 99, 185, 191, 196
- Metastasis 124, 151
- Mini-Cells 1, 202
- Monocyte 13, 86, 105
- Muramyl tripeptide 61

## N

- Natural killer cell 96, 172
- Neuroblastoma
  - Murine 117
- Nocardia rubra* cell wall skeleton 67

## P

- Propionibacterium acnes* 10

## R

- Radioimmunoassay 185

## S

- Salmonella typhimurium* 1, 202
- Serotherapy 117

## T

- T-cell-subsets 16
  - Lines 73
- Receptors 133
  - Growth factor 205
- Thymosin 145
- Tumor Cell
  - In vivo clearance 172
- Tumour
  - Antibodies 180
  - Bladder 82
  - Immunogenicity 27
  - Lung 13
  - Necrosis factor 41
  - Prostate 155
  - Specific transplantation antigens 133
  - Suppression 36
  - Variants 124

# Subject Index

## A

- ADCC 96, 117
- Adrenoceptor
  - Blockade 41
- Adriamycin 61
- Alloimmunity 46
- Allosensitization
  - Melanoma 99
- Antibody
  - Monoclonal 155, 196
  - Tumour 180
  - Xenogeneic 191
- Antigen
  - Fetal 78
  - Histocompatibility 133
  - Melanoma 191, 196
  - Murine leukemia 16
- Auto tumour stimulation 73

## B

- BCG 46, 92
- BCG-MER 4
- BCG-cell wall skeleton 167
- Brucella abortus 207

## C

- Chemiluminescence 86
- Chemoimmunotherapy 67, 202
- Cyclophosphamide 36
- Cytotoxicity
  - Lymphocyte 45, 54, 73, 82, 96, 99, 117, 137
  - Macrophage 61, 67

## E

- Endotoxin 41
- Epidemiology 110

## G

- Gastric cancer 167, 180

## H

- Helper cells 46
- Hepatoma
  - Line 10, 92, 151
- Hypersensitivity
  - Delayed type 59

## I

- Immunogenicity
  - Tumour 27
- Immunorestitution 145
- Immunoselection
  - Tumor variants 124
- Immunosuppression
  - Cyclophosphamide 36, 54
  - Tumour 36, 86
- Immunotherapy 4, 92, 151, 167
- Interferon 41

## K

- Klebsiella pneumoniae* 59

## L

- Leukemia
  - Acute 96
  - Murine 16
  - Myeloid 32
- Leukocytes
  - Migration assay 78
- Liposomes 61
- Lymphocyte
  - Cytotoxicity 54, 82, 99, 137
  - Helper 32
  - Suppressor 32

## M

- Macrophage 61, 67, 105
- Melanoma 78, 99, 185, 191, 196
- Metastasis 124, 151
- Mini-Cells 1, 202
- Monocyte 13, 86, 105
- Muramyl tripeptide 61

## N

- Natural killer cell 96, 172
- Neuroblastoma
  - Murine 117
- Nocardia rubra* cell wall skeleton 67

## P

- Propionibacterium acnes* 10

## R

- Radioimmunoassay 185

## S

- Salmonella typhimurium* 1, 202
- Serotherapy 117

## T

- T-cell-subsets 16
  - Lines 73
- Receptors 133
  - Growth factor 205
- Thymosin 145
- Tumor Cell
  - In vivo clearance 172
- Tumour
  - Antibodies 180
  - Bladder 82
  - Immunogenicity 27
  - Lung 13
  - Necrosis factor 41
  - Prostate 155
  - Specific transplantation antigens 133
  - Suppression 36
  - Variants 124



V

Ed

R.

Ed

M.

E.

P.

J.-C.

G.

F.

S.

S.P.

A.

R.

K.

R.

# Cancer Immunology Immunotherapy

Founding Editor  
G. Mathé

Other Biological Response Modifications

Volume 14 1983

## Editors in Chief

**R. W. Baldwin E. Mihich**

## Editorial Board

**M. Boranic** Zagreb  
**E. C. Borden** Madison  
**P. Burtin** Villejuif  
**J.-C. Cerottini** Epalinges  
**G. Della Porta** Milano  
**F. Deinhardt** Munich  
**S. Dray** Chicago  
**S. Ferrone** New York  
**A. Goldstein** Washington  
**R. Good** New York  
**K. Hellstrom** Seattle  
**R. Herberman** Bethesda

**L. Israël** Bobigny  
**K. Karrer** Vienna  
**G. Klein** Stockholm  
**H. Kobayashi** Sapporo  
**A. LoBuglio** Ann Arbor  
**M. Mastrangelo** Philadelphia  
**P. Minden** Denver  
**D. Morton** Los Angeles  
**H. M. Pinedo** Amsterdam  
**R. Oldham** Frederick  
**P. Reizenstein** Stockholm  
**G. Riethmüller** Munich

**M. Rittenberg** Portland  
**B. Serrou** Montpellier  
**J. Stjernswärd** Geneva  
**H. Umezawa** Tokyo  
**D. W. van Bekkum** Rijswijk  
**N. Warner** Mountain View  
**D. Weiss** Jerusalem  
**M. F. A. Woodruff** Edinburgh  
**Y. Yagi** Kamakura City  
**K. Yamamoto** Kanazawa  
**Y. Yamamura** Osaka



Springer International

## **Cancer Immunology and Immunotherapy**

### **Other Biological Response Modifications**

This journal was founded in 1976. Editors: R. W. Baldwin, G. Mathé, E. Mihich.  
Published by Springer International.

The exclusive copyright for all languages and countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Authors of this journal can benefit from library and photocopy fees collected by VG WORT if certain conditions are met. If an author lives in the Federal Republic of Germany or in West Berlin it is recommended that he contacts Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, for detailed information.

Die Wiedergabe von Gebrauchsnamen, Handelsnamen, Warenbezeichnungen usw. in dieser Zeitschrift berechtigt auch ohne besondere Kennzeichnung nicht zu der Annahme, daß solche Namen im Sinne der Warenzeichen- und Markenschutz-Gesetzgebung als frei zu betrachten wären und daher von jedermann benutzt werden dürften.

Die in der Zeitschrift veröffentlichten Beiträge sind urheberrechtlich geschützt. Alle Rechte, insbesondere das der Übersetzung in fremde Sprachen, vorbehalten. Kein Teil dieser Zeitschrift darf ohne schriftliche Genehmigung des Verlages in irgendeiner Form – durch Fotokopie, Mikrofilm oder andere Verfahren – reproduziert oder in eine von Maschinen, insbesondere von Datenverarbeitungsanlagen, verwendbare Sprache übertragen werden.

Auch die Rechte der Wiedergabe durch Vortrag, Funk- und Fernsehsendung, im Magnettonverfahren oder ähnlichem Wege bleiben vorbehalten.

Fotokopien für den persönlichen und sonstigen eigenen Gebrauch dürfen nur von einzelnen Beiträgen oder Teilen daraus als Einzelkopien hergestellt werden. Jede im Bereich eines gewerblichen Unternehmens hergestellte oder benutzte Kopie dient gewerblichen Zwecken gem. § 54 (2) UrhG und verpflichtet zur Gebührenzahlung an die VG WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2, von der die einzelnen Zahlungsmodalitäten zu erfragen sind.

Autoren dieser Zeitschrift können unter gewissen Voraussetzungen in die Individualauschüttung von Mitteln aus der Bibliothekantientie und dem Fotokopieraufkommen mit einbezogen werden. Genaue Informationen erteilt die Verwertungsgesellschaft WORT, Abteilung Wissenschaft, Goethestraße 49, D-8000 München 2.

Springer-Verlag Berlin Heidelberg New York Tokyo

Printers: Carl Ritter GmbH & Co. KG, Wiesbaden

Printed in Germany · © Springer-Verlag Berlin Heidelberg 1982/83



Ta

Ahi

Ir

S

S

ti

T

Ale

Are

S

R

a

g

Asa

Bal

Bal

Ber

Ber

Ber

T

F

(

Bi

Bi

Bi

I

I

Bo

Br

## Table of Contents

Ahituv, A., Naor, D., Sharon, R., Tarcic, N., Klein, B. Y.: Immunogenicity of Subcellular Fractions and Molecular Species of MuLV-Induced Tumors: III. Stimulation of Syngeneic Antitumor Responses by Subcellular Fractions and Molecular Species of Moloney Virus-Induced Tumors in CBA and A Mice 16

Aleksijevic, A., see Lang, J.-M., et al. 59

Arends-Merino, A., Giscombe, R., Ogier, C., Reizenstein, P., Sjörgen, A.-M., Wasserman, J.: Modifying the Biological Response in Acute Myeloid Leukemia: II. Effect of BCG and Leukemic Cells on Lymphocyte Response to Mitogens, and on Helper and Suppressor Activity 32

Asano, T., see Ochiai, T., et al. 167

Baldwin, R. W., see Gerlier, D., et al. 27

Balsari, A., see Fossati, G., et al. 99

Benaissa-Trouw, B., see Bloksma, N., et al. 41

Bennedsen, J., see Nielsen, H., et al. 13

Berczi, I., Holford-Strevens, V., Warsi, Z. H., McMorris, L. S., Thorlakson, R. H., Thorlakson, T. K., Sehon, A. H.: Tumor-Reactive IgE Antibodies in Plasma of Patients with Gastrointestinal Carcinomas 180

Bielski, M., see Talpaz, M., et al. 96

Bisby, R. H., see Gerlier, D., et al. 27

Bloksma, N., Hofhuis, F., Benaissa-Trouw, B., Willers, J.: Endotoxin-Induced Release of Tumour Necrosis Factor and Interferon *in vivo* is Inhibited by Prior Adrenoceptor Blockade 41

Boer, K. P. De, see Braun, D. P., et al. 86

Braun, D. P., Boer, K. P. De, Harris, J. E.: Chemiluminescence, Suppression and Cytotoxicity in Peripheral Blood Mononuclear Cells from Solid Tumor Cancer Patients 86

Briner, W. H., see Webb, K. S., et al. 155

Brunda, M. J., see Wiltz, R. H., et al. 172

Bubeník, J., Perlmann, P., Indrová, M., Simová, J., Jandlová, T., Neuwirt, J.: Growth Inhibition of an MC-Induced Mouse Sarcoma by TCGF (IL-2)-Containing Preparations: Preliminary Report 205

Byfield, J. E., Zerubavel, R., Fonkalsrud, E. W.: Antibody-Dependent Cellular Cytotoxicity-Mediated Serotherapy Against Murine Neuroblastoma. I. *In vitro* and *In vivo* Treatment Using Normal,  $\gamma$ -Irradiated and Immune-Stimulated Rat Effector Cells 117

Cochran, A. J., Todd, G., Hart, D. M., Morrison, L. J. A., MacKie, R. M.: Reaction of the Leucocytes of Melanoma Patients and Control Donors, Including Pregnant Women, with Melanoma- and Fetus-Derived Materials 78

Collet, B., Dazord, L., Portoukalian, J., Sauvager, F., Ruffault, A., David, C.: Influence of the Culture Conditions of *Brucella abortus* on its Antitumor Properties 207

Culò, F., see Vidović, D., et al. 36

David, C., see Collet, B., et al. 207

Davies, M., Sabbadini, E.: Mechanisms of BCG Action: I. The Induction of Nonspecific Helper Cells During the Potentiation of Alloimmune Cell-Mediated Cytotoxic Responses 46

Davis, W. C., see Starkey, J. R., et al. 124

Dazord, L., see Collet, B., et al. 207

Dombernowsky, P., see Nielsen, H., et al. 13

Farr, R. S., see Kelleher, P. J., et al. 185

Ferrone, S., see Wilson, B. S., et al. 196

Fidler, I. J., see Hisano, G. 61

Fonkalsrud, E. W., see Byfield, J. E., et al. 117

Fossati, G., Balsari, A., Taramelli, D., Sensi, M. L., Pellegrini, G., Nava, M., Parmiani, G.: Lysis of Autologous Human Melanoma Cells by *in vitro* Allosensitized Peripheral Blood Lymphocytes 99

Fredrickson, G., see Silobricic, V., et al. 10

Gerlier, D., Price, M. R., Bisby, R. H., Baldwin, R. W.: Modification of Cell Cholesterol Content of Rat Tumour Cells: Effect Upon Their Tumorigenicity and Immunogenicity 27

Giron, C., see Lang, J.-M., et al. 59

Giscombe, R., see Arends-Merino, A., et al. 32

Gorelik, E., see Wiltz, R. H., et al. 172

Gschwind, C., see Hersh, E. M., et al. 105

Gutterman, J. U., see Hersh, E. M., et al. 4

Hancock, E. J., Kilburn, D. G.: The Effects of Cyclophosphamide on *in vitro* Cytotoxic Responses to a Syngeneic Tumour 54

Harris, J. E., see Braun, D. P., et al. 86

Hart, D. M., see Cochran, A. J., et al. 78

Hayashi, R., see Ochiai, T., et al. 167

Herberman, R. B., see Wiltz, R. H., et al. 172

Hersh, E. M., Gschwind, C., Morris, D. L., Murphy, S.: Deficient Strongly Adherent Monocytes in the Peripheral Blood of Cancer Patients 105

Hersh, E. M., Quesada, J., Murphy, S. G., Gutterman, J. U., Hutchins, R. D.: Evaluation of Therapy with Methanol Extraction Residue of BCG (MER) 4

Hersh, E. M., see Talpaz, M., et al. 96

Hisano, G., Fidler, I. J.: Systemic Activation of Macrophages by Liposome-Entrapped Muramyl Tripeptide in Mice Pretreated with the Chemotherapeutic Agent Adriamycin 61

Hofhuis, F., see Bloksma, N., et al. 41

Holden, H. T., see Wiltz, R. H., et al. 172

Holford-Strevens, V., see Berczi, I., et al. 180

Hunter, J. T., see Sukumar, S., et al. 151

Hunter, J. T., see Yarkoni, E., et al. 92

Hutchins, R. D., see Hersh, E. M., et al. 4

Indrová, M., see Bubeník, J., et al. 205

Ishitsuka, H., Umeda, Y., Nakamura, J., Yagi, Y.: Protective Activity of Thymosin Against Opportunistic Infections in Animal Models 145

Jandlová, T., see Bubeník, J., et al. 205

Kelleher, P. J., Mathews, H. L., Moore, G. E., Minden, P.: The Use of Cellular Immunoabsorbents to Prepare Polyclonal Antibodies that Distinguish Between Antigens Derived from Human Melanoma Cells and Autologous Lymphocytes 191

Kelleher, P. J., Mathews, H. L., Woods, L. K., Farr, R. S., Minden, P.: A Solid-Phase Radioimmunoassay to Detect Antibodies Produced by Hybridomas to Antigens Derived from Human Melanoma Cells 185

Kilburn, D. G., see Hancock, E. J. 54

Kishimoto, S., see Ogura, T., et al. 67

Klein, B. Y., see Ahituv, A., et al. 16

Klein, E., see Vánky, F. 73

Kneale, G. W., see Stewart, A. M. 110

Kodama, K., see Kurashige, S., et al. 202

Kurashige, S., Kodama, K., Yoshida, T.: Synergistic Anti-Tumor Effect of Mini-Cells Prepared from *Salmonella typhimurium* with Mitomycin C in EL4-Bearing Mice 202

**Kurashige, S., Mitsuhashi, S.:** Enhancing Effects of Mini-Cells Prepared From *Salmonella typhimurium* on Anti-Tumor Immunity in Sarcoma 180-Bearing Mice 1

**Lang, J.-M., Giron, C., Aleksijevic, A., Marchiani, C., Zalisz, R., Oberling, F.:** Enhancement of Delayed Cutaneous Hypersensitivity in Untreated Cancer Patients Given a Short-Term Oral Treatment with C 1821 59

**Larsson, Å., Näslund, I., Troye, M.:** A Follow-Up Study of Urinary Bladder Patients Tested for Tumour-Related Lymphocyte-Mediated Cytotoxicity 82

**MacKie, R. M.,** see Cochran, A. J., et al. 78

**Marchiani, C.,** see Lang, J.-M., et al. 59

**Marušić, M.,** see Vidović, D., et al. 36

**Mathews, H. L.,** see Kelleher, P. J., et al. 185

**Mathews, H. L.,** see Kelleher, P. J., et al. 191

**McMorris, L. S.,** see Berczi, I., et al. 180

**Minden, P.,** see Kelleher, P. J., et al. 185

**Minden, P.,** see Kelleher, P. J., et al. 191

**Mitsuhashi, S.,** see Kurashige, S. 1

**Moore, G. E.,** see Kelleher, P. J., et al. 191

**Morris, D. L.,** see Hersh, E. M., et al. 105

**Morrison, L. J. A.,** see Cochran, A. J., et al. 78

**Murphy, S.,** see Hersh, E. M., et al. 105

**Murphy, S. G.,** see Hersh, E. M., et al. 4

**Nakamura, J.,** see Ishitsuka, H., et al. 145

**Namba, M.,** see Ogura, T., et al. 67

**Naor, D.,** see Ahituv, A., et al. 16

**Näslund, I.,** see Larsson, Å., et al. 82

**Nava, M.,** see Fossati, G., et al. 99

**Neuwirt, J.,** see Bubenik, J., et al. 205

**Nielsen, H., Bennedsen, J., Dombernowsky, P.:** Normalization of Defective Monocyte Chemotaxis During Chemotherapy in Patients with Small Cell Anaplastic Carcinoma of the Lung 13

**Oberling, F.,** see Lang, J.-M., et al. 59

**Ochiai, T., Sato, H., Hayashi, R., Asano, T., Sato, H., Yamamura, Y.:** Postoperative Adjuvant Immunotherapy of Gastric Cancer with BCG-Cell Wall Skeleton: 3- to 6-Year Follow up of a Randomized Clinical Trial 167

**Ogier, C.,** see Arends-Merino, A., et al. 32

**Ogura, T., Shintzato, O., Sakatani, M., Shindo, H., Namba, M., Kishimoto, S., Yamamura, Y.:** Analysis of Therapeutic Effect in Experimental Chemoimmunotherapy for Rat Ascites Tumor 67

**Parks, S. F.,** see Webb, K. S., et al. 155

**Parmiani, G.,** see Fossati, G., et al. 99

**Parmiani, G., Pierotti, M. A.:** Generation of TSTA Diversity: Looking for Testable Hypotheses 133

**Paulson, D. F.,** see Webb, K. S., et al. 155

**Pellegris, G.,** see Fossati, G., et al. 99

**Perlmann, P.,** see Vilien, M., et al. 137

**Perlmann, P.,** see Bubenik, J., et al. 205

**Pierotti, M. A.,** see Parmiani, G. 133

**Portoukalian, J.,** see Collet, B., et al. 207

**Price, M. R.,** see Gerlier, D., et al. 27

**Quesada, J.,** see Hersh, E. M., et al. 4

**Rapp, H. J.,** see Sukumar, S., et al. 151

**Rasmussen, F.,** see Vilien, M., et al. 137

**Reizenstein, P.,** see Arends-Merino, A., et al. 32

**Ruberto, G.,** see Wilson, B. S., et al. 196

**Ruffault, A.,** see Collet, B., et al. 207

**Sabbadini, E.,** see Davies, M. 46

**Sakatani, M.,** see Ogura, T., et al. 67

**Sato, H.,** see Ochiai, T., et al. 167

**Sato, H.,** see Ochiai, T., et al. 167

**Sauvager, F.,** see Collet, B., et al. 207

**Sedlacek, R.,** see Silobrcic, V., et al. 10

**Sehon, A. H.,** see Berczi, I., et al. 180

**Sensi, M. L.,** see Fossati, G., et al. 99

**Sharon, R.,** see Ahituv, A., et al. 16

**Shindo, H.,** see Ogura, T., et al. 67

**Shintzato, O.,** see Ogura, T., et al. 67

**Silobrcic, V., Fredrickson, G., Sedlacek, R., Suit, H. D., Wolberg, G.:** Immune Reaction of Tumor-Bearing Mice to *Propionibacterium acnes* and the Antitumor Effect of the Bacteria 10

**Šimová, J.,** see Bubeník, J., et al. 205

**Sjörgen, A.-M.,** see Arends-Merino, A., et al. 32

**Starkey, J. R., Davis, W. C., Talmadge, J. E.:** Immuno-selection of Tumor Variants Resistant to Antibody-Mediated Cytotoxicity. Their Immunologic and Metastatic Characterization 124

**Stewart, A. M., Kneale, G. W.:** The Immune System and Cancers of Foetal Origin 110

**Suit, H. D.,** see Silobrcic, V., et al. 10

**Sukumar, S., Hunter, J. T., Terata, N., Rapp, H. J.:** Eradication of Microscopic Hepatic Metastases by Active Specific Immunotherapy 151

**Sukumar, S.,** see Yarkoni, E., et al. 92

**Talmadge, J. E.,** see Starkey, J. R., et al. 124

**Talpaz, M., Bielski, M., Hersh, E. M.:** Studies of Natural Killer Cell Activity and Antibody-Dependent Cell-Mediated Cytotoxicity Among Patients with Acute Leukemia in Complete Remission 96

**Taramelli, D.,** see Fossati, G., et al. 99

**Tarcic, N.,** see Ahituv, A., et al. 16

**Terata, N.,** see Sukumar, S., et al. 151

**Thorlakson, R. H.,** see Berczi, I., et al. 180

**Thorlakson, T. K.,** see Berczi, I., et al. 180

**Todd, G.,** see Cochran, A. J., et al. 78

**Troye, M.,** see Larsson, Å., et al. 82

**Troye-Blomberg, M.,** see Vilien, M., et al. 137

**Umeda, Y.,** see Ishitsuka, H., et al. 145

**Vánky, F., Klein, E.:** Human T-Cell Cultures with Selective Autotumor Reactivity 73

**Vidović, D., Marušić, M., Čulo, F.:** Interference of Anti-Tumor and Immunosuppressive Effects of Cyclophosphamide in Tumor-Bearing Rats: Analysis of Factors Determining Resistance or Susceptibility to a Subsequent Tumor Challenge 36

**Vilien, M., Troye-Blomberg, M., Perlmann, P., Wolf, H., Rasmussen, F.:** Human Spontaneous Lymphocyte-Mediated Cytotoxicity (SLMC) Against Malignant and Normal Tissue-Derived Target Cell Lines Tested in Autologous and Allogeneic Combinations by the Microcytotoxicity Assay 137

**Ware, J. L.,** see Webb, K. S., et al. 155

**Warsi, Z. H.,** see Berczi, I., et al. 180

**Wasserman, J.,** see Arends-Merino, A., et al. 32

**Webb, K. S., Ware, J. L., Parks, S. F., Briner, W. H., Paulson, D. F.:** Monoclonal Antibodies to Different Epitopes on a Prostate Tumor-Associated Antigen: Implications for Immunotherapy 155

**Willers, J.,** see Bloksma, N., et al. 41

**Wilson, B. S., Ruberto, G., Ferrone, S.:** Immunochemical Characterization of a Human High Molecular Weight Melanoma Associated Antigen Identified with Monoclonal Antibodies 196

**Wiltrot, R. H., Gorelik, E., Brundá, M. J., Holden, H. T., Herberman, R. B.:** Assessment of in vivo Natural Antitumor Resistance and Lymphocyte Migration in Mice

Comparison of  $^{125}\text{I}$ -Iododeoxyuridine with  $^{111}\text{In}$ -Indium-Oxine and  $^{51}\text{Cr}$ -Chromium as Cell Labels 172  
Wolberg, G., see Silobrcic, V., et al. 10  
Wolf, H., see Vilien, M., et al. 137  
Woods, L. K., see Kelleher, P. J., et al. 185  
Yagi, Y., see Ishitsuka, H., et al. 145  
Yamamura, Y., see Ochiai, T., et al. 167  
Yamamura, Y., see Ogura, T., et al. 67

Yarkoni, E., Hunter, J. T., Sukumar, S.: A Specific Vaccine Effective Against Stage I and Stage II Malignant Disease in Guinea Pigs. Effect of Variations in Preparations and Storage 92  
Yoshida, T., see Kurashige, S., et al. 202  
Zalisz, R., see Lang, J.-M., et al. 59  
Zerubavel, R., see Byfield, J. E., et al. 117